Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 16 2023 - 6:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2023
Commission File Number: 001-37452
CELYAD ONCOLOGY SA
(Translation of registrants name into English)
Rue Edouard
Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by
check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40- F.
Form
20-F ☒ Form 40-F ☐
Celyad Oncology SA
On May 15, 2023, Celyad Oncology SA (the Company) issued a press release announcing that it received a notification letter from The
Nasdaq Stock Market (Nasdaq) (the Notice), advising the Company that its American Depositary Shares representing ordinary shares (ADSs) are scheduled for delisting from The Nasdaq Global Market and
will be suspended at the opening of U.S. business on May 19, 2023.
The Notice stated that Nasdaq has determined that the Company did not provide a
definitive plan evidencing its ability to achieve near term compliance with the continued listing requirements or sustain such compliance over an extended period of time. The Company does not intend to appeal Nasdaqs determination and,
therefore, it is expected that the Companys ADSs will be delisted from the Nasdaq Global Market on May 19, 2023. A Form 25-NSE will be filed with the U.S. Securities and Exchange Commission (the
SEC), which will remove the Companys ADSs from listing on Nasdaq. The Company will continue to be listed on Euronext Brussels. Whether or not the Companys ADSs will be traded on the over-the-counter market thereafter will depend on the actions of shareholders and independent third parties, without the Companys involvement.
The Companys press release also contains additional information for the Companys ADS holders.
A copy of the Companys press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information contained in this Current Report on Form 6-K, including Exhibit 99.1 is hereby incorporated by
reference into the Companys Registration Statements on Forms F-3 (File No. 333-248464) and S-8 (File No. 333- 220737).
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CELYAD ONCOLOGY SA |
|
|
|
|
Date: May 16, 2023 |
|
|
|
By: |
|
/s/ Georges Rawadi |
|
|
|
|
|
|
Georges Rawadi |
|
|
|
|
|
|
Chief Executive Officer |
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Apr 2023 to Apr 2024